Cytonics has announced the conclusion of subject enrolment in a Phase I clinical trial of CYT-108, for use as putative disease-modifying therapy for osteoarthritis (OA) of the knee. CYT-108 is a ...
Thursday, Oct 3rd @ 7:00pm Friday, Oct 4th @ 9:00am Friday, Oct 4th @ 11:30am Friday, Oct 4th @ 7:00pm Saturday, Oct 5th @ 2:00pm Saturday, Oct 5th @ 7:00pm Sunday, Oct 6th @ 2:00pm * Prices may vary ...